Mouse monoclonal antibody for human lipid phosphate phosphatase-3 (LPP3)

Sept. 10, 2015

UIC inventors have developed a mouse monoclonal antibody which recognizes human lipid phosphate phosphohydrolase 3 (LPP3).
An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro. In addition, LPP3 not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway.
LPP3 also has the ability to potentiate tumor growth by amplifying B-catenin and CYCLIN-D1 activities. Thus, LPP3 is a potential target for inhibiting the growth of glioblastoma (an aggressive type of brain tumor) and other tumors that express high levels of LPP3, and may serve as a link in the acquisition of proliferative, invasive, and metastatic phenotypes.

A potential anti-tumor therapeutic and/or research tool that works through inhibiting angiogenesis. Can be used for the identification of transformed cells in archival pathological tissue samples such as angiomas, angiosarcomas, endothelioma, pancreatic tumors, and glioblastoma tumors
An antibody that has been validated for use in western blotting, immunoprecipitation, and flow cytometry
A research tool for the identification of transformed cells in archival pathological tissue samples such as angiomas, angiosarcomas, endothelioma, pancreatic tumors, and glioblastoma tumors
A potential anti-tumor therapeutic and/or research tool that works through inhibiting angiogenesis

由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。